PolyPeptide Group AG
Symbol: PPGN.SW
SIX
30.85
CHFTrhová cena dnes
-20.2422
Pomer P/E
-0.4777
Pomer PEG
1.02B
MRK Cap
- 0.00%
Výnos DIV
PolyPeptide Group AG (PPGN-SW) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 279.04 | 101.1 | 49.1 | 67.8 | ||||||
balance-sheet.row.inventory | 564.08 | 128.5 | 145.1 | 113 | ||||||
balance-sheet.row.other-current-assets | 71.69 | 1.3 | 19.8 | 14.5 | ||||||
balance-sheet.row.total-current-assets | 1123.47 | 326.6 | 251.6 | 331.6 | ||||||
balance-sheet.row.property-plant-equipment-net | 1190.14 | 324.1 | 297.3 | 235.4 | ||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.long-term-investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.tax-assets | 42.61 | 16.7 | 8.3 | 10.3 | ||||||
balance-sheet.row.other-non-current-assets | -25.92 | 0 | -8.3 | -10.3 | ||||||
balance-sheet.row.total-non-current-assets | 1283.86 | 362.5 | 315.9 | 253.2 | ||||||
balance-sheet.row.other-assets | 25.92 | 0 | 8.3 | 10.3 | ||||||
balance-sheet.row.total-assets | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.account-payables | 160.69 | 60.9 | 45.9 | 28.5 | ||||||
balance-sheet.row.short-term-debt | 111.1 | 45.7 | 3.6 | 3.1 | ||||||
balance-sheet.row.tax-payables | 17.52 | 9.3 | 4.9 | 7.6 | ||||||
balance-sheet.row.long-term-debt-total | 97 | 68 | 9.4 | 10.3 | ||||||
Deferred Revenue Non Current | 47.26 | 23.2 | 7.5 | 9.2 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 8.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 237.3 | 1.4 | 50.1 | 75.5 | ||||||
balance-sheet.row.total-non-current-liabilities | 160.46 | 131.4 | 9.4 | 10.3 | ||||||
balance-sheet.row.other-liabilities | 146.11 | 0 | 48.6 | 59.6 | ||||||
balance-sheet.row.capital-lease-obligations | 87.25 | 23.3 | 21.2 | 18 | ||||||
balance-sheet.row.total-liab | 818.72 | 307.9 | 154.1 | 173.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 1.21 | 0.3 | 0.3 | 0.3 | ||||||
balance-sheet.row.retained-earnings | 775.36 | 165.1 | 214.1 | 196 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 74.69 | 23 | 17.7 | 13.2 | ||||||
balance-sheet.row.other-total-stockholders-equity | 763.27 | 192.7 | 189.5 | 211.6 | ||||||
balance-sheet.row.total-stockholders-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 2433.25 | - | - | - | ||||||
Total Investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.total-debt | 232.77 | 113.7 | 21.2 | 18 | ||||||
balance-sheet.row.net-debt | 24.11 | 18 | -16.3 | -118.3 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.47 | 30.5 | 24 | 18.7 | ||||||
cash-flows.row.deferred-income-tax | 46.42 | 3.1 | 13.2 | 28.7 | ||||||
cash-flows.row.stock-based-compensation | 2.05 | 0.8 | 1.2 | 1.2 | ||||||
cash-flows.row.change-in-working-capital | -29.34 | 46.2 | -14.3 | -29.9 | ||||||
cash-flows.row.account-receivables | -10.56 | 0 | 18.8 | -12.2 | ||||||
cash-flows.row.inventory | -17.62 | 15.5 | -33.1 | -17.7 | ||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-working-capital | -1.16 | 30.7 | 0 | 0 | ||||||
cash-flows.row.other-non-cash-items | 63.45 | 7.3 | -26.3 | -8.6 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 41.95 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | -9.95 | -2.8 | -3.3 | -6.9 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -137.95 | -59.5 | -78.4 | -80.8 | ||||||
cash-flows.row.debt-repayment | -3.51 | -55.2 | -3.3 | -41.4 | ||||||
cash-flows.row.common-stock-issued | 13.79 | 0 | 17.2 | 182.1 | ||||||
cash-flows.row.common-stock-repurchased | -13.93 | 0 | -13.9 | -5.5 | ||||||
cash-flows.row.dividends-paid | -9.67 | 0 | -9.7 | -135.3 | ||||||
cash-flows.row.other-financing-activites | 71.01 | 139.7 | -17.2 | 130.9 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 57.68 | 84.5 | -26.9 | 130.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | -2.27 | -3.3 | 1.1 | 11.7 | ||||||
cash-flows.row.net-change-in-cash | -40.6 | 58.2 | -98.8 | 119.1 | ||||||
cash-flows.row.cash-at-end-of-period | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 249.25 | 37.5 | 136.3 | 17.2 | ||||||
cash-flows.row.operating-cash-flow | 41.95 | 36.5 | 5.5 | 57.4 | ||||||
cash-flows.row.capital-expenditure | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.free-cash-flow | -86.05 | -20.2 | -69.6 | -16.6 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 601.35 | 320.4 | 281 | 282.1 | ||||||
income-statement-row.row.cost-of-revenue | 544.59 | 315.7 | 229 | 182.4 | ||||||
income-statement-row.row.gross-profit | 56.76 | 4.6 | 52 | 99.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 2.71 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 70.54 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.operating-expenses | 99.79 | 41.1 | 42.3 | 37 | ||||||
income-statement-row.row.cost-and-expenses | 644.37 | 356.8 | 271.3 | 219.5 | ||||||
income-statement-row.row.interest-income | 8.77 | 0.1 | 2.1 | 2.8 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.total-operating-expenses | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.depreciation-and-amortization | 42.05 | 30.5 | 20.5 | 16.1 | ||||||
income-statement-row.row.ebitda-caps | 20.74 | - | - | - | ||||||
income-statement-row.row.operating-income | -21.3 | -36.5 | 12.5 | 67.4 | ||||||
income-statement-row.row.income-before-tax | -50.68 | -58.2 | 7.6 | 59.8 | ||||||
income-statement-row.row.income-tax-expense | 12.19 | -6.8 | 0.2 | 12.6 | ||||||
income-statement-row.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 |
Často kladené otázky
Čo je PolyPeptide Group AG (PPGN.SW) celkové aktíva?
PolyPeptide Group AG (PPGN.SW) celkové aktíva sú 689088000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 320372000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.015.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -0.498.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -0.161.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.106.
Aká je PolyPeptide Group AG (PPGN.SW) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -51440000.000.
Aký je celkový dlh firmy?
Celkový dlh je 113662000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 41110000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 95706000.000.